Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Mitochondrial Regulation Is Essential for Erythroid Nuclear Clearance

Raymond Liang, PhD, Vijay Menon, PhD, Miao Lin, Msc, Roberta Nowak, Velia M. Fowler, PhD, Geoffrey Girnun, Saghi Ghaffari, MDPhD

Blood (2018) 132 (Supplement 1): 843.

https://doi.org/10.1182/blood-2018-99-120063

Published: 2018

Journal Articles

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Muhammad Jahanzeb Khalil, MD, Faisal Mahfooz, MD, Madeeha Shafqat, Anum Qureshi, Insija Ilyas Selene, MBBS, Syed Shabee Hassan, MD, Muhammad Junaid Tariq, MD, Muhammad Yasir, MD, Sharoon Samuel, MBBS, Maryam Sadiq, MBBS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2018-99-111587

Published: 2018

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MDPhD, Cristina Motllo, Paula Rodriguez-Otero, MD PhD, Joaquin Martinez-Lopez, MD PhD, Javier de la Rubia, Jesús Martín, Joan Bladé, MD PhD, María-Dolores García-Malo, Luis Palomera, Aránzazu García-Mateo, Felipe De Arriba, PhD, Ramón García-Sanz, MD, Albert Oriol, MD, Juan-José Lahuerta, Jesus F. San Miguel, MD, Maria-Victoria Mateos, MD

Blood (2017) 130 (Supplement 1): 1873.

https://doi.org/10.1182/blood.V130.Suppl_1.1873.1873

Published: 2017

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MD PhD, Cristina Motlló, MD, Paula Rodriguez-Otero, MD PhD, Joaquín Martínez-López, MD PhD, Javier De La Rubia, Mieke Ptaszynski, Brian Tunquist, Ramon Garcia-Sanz, MD PhD, Albert Oriol, Juan José Lahuerta, MD PhD, Jesús San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD

Blood (2016) 128 (22): 4503.

https://doi.org/10.1182/blood.V128.22.4503.4503

Published: 2016

Journal Articles

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Blood (2015) 126 (23): 728.

https://doi.org/10.1182/blood.V126.23.728.728

Published: 2015

Journal Articles

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Luis A Corchete, Teresa Paíno, Ana Alicia López-Iglesias, Esperanza Macarena Algarín, Mercedes Garayoa, Brian Tunquist, Norma C Gutierrez, Maria-Victoria Mateos, MD PhD, Enrique M Ocio

Blood (2015) 126 (23): 1801.

https://doi.org/10.1182/blood.V126.23.1801.1801

Published: 2015

Journal Articles

Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism

Susana Hernández-García, Lorena González-Méndez, Irena Misiewicz-Krzeminska, Esperanza Macarena Algarín, Ana Alicia López-Iglesias, Laura San-Segundo, Montserrat Martín-Sánchez, Teresa Paíno, Norma C Gutierrez, Mercedes Garayoa, Brian Tunquist, Maria-Victoria Mateos, Enrique M Ocio

Blood (2015) 126 (23): 5353.

https://doi.org/10.1182/blood.V126.23.5353.5353

Published: 2015

Journal Articles

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Andreas R. Thomsen, MD, Claudius Klein, Christine Aldrian, Martin Kortuem, MD, Marie Follo, PhD, Julia Schüler, DVM, PhD, Justus Duyster, MD PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 1822.

https://doi.org/10.1182/blood.V126.23.1822.1822

Published: 2015

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, MD, Lei Feng, MS, Sheeba K. Thomas, MD, Donna Weber, MD, Michael Wang, MD, Elisabet E. Manasanch, MD, Kathleen Mendoza, RN, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 376.

https://doi.org/10.1182/blood.V126.23.376.376

Published: 2015

Journal Articles

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Teresa Paíno, PhD, Ana Alicia López-Iglesias, MD, Montserrat Martín-Sánchez, Mercedes Garayoa, PhD BS, Michael J Humphries, PhD, Brian Tunquist, PhD BS, Maria-Victoria Mateos, Enrique M Ocio, MD PhD

Blood (2014) 124 (21): 4710.

https://doi.org/10.1182/blood.V124.21.4710.4710

Published: 2014

Journal Articles

Kurowska M, Goudin N, Nehme NT, et al. Terminal transport of lytic granules to the immune synapse is mediated by the kinesin-1/Slp3/Rab27a complex. Blood . 2012;119(17): 3879-3889 .

Blood (2014) 123 (9): 1432.

https://doi.org/10.1182/blood-2014-01-550004

Published: 2014

Journal Articles

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, M.D., Lei Feng, M.S., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Brandi Hilder, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1982.

https://doi.org/10.1182/blood.V122.21.1982.1982

Published: 2013

Journal Articles

ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma

Michael J Humphries, PhD, Deborah Anderson, Lance Williams, Rob Rieger, Brian Tunquist, PhD, Duncan Walker, PhD

Blood (2013) 122 (21): 3167.

https://doi.org/10.1182/blood.V122.21.3167.3167

Published: 2013

Journal Articles

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Dongmin Gu, M.D., Ph.D., Hua Wang, Ph.D., Zhiqiang Wang, Ph.D., Richard E. Davis, M.D., Shengli Cai, M.D., Ph.D., Takahiko Seki, Ph.D., Archie Tse, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D

Blood (2013) 122 (21): 1927.

https://doi.org/10.1182/blood.V122.21.1927.1927

Published: 2013

Journal Articles

Whole Exome Sequencing Detecting Kinesin Family Gene Defects In Myeloid Neoplasm

Chantana Polprasert, MD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Naoko Hosono, MD, PhD, Wenyi Shen, MD, Dayong Huang, MD, Yuichi Shiraishi, PhD, Satoru Miyano, PhD, Kenichi Yoshida, MD, Seishi Ogawa, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 2762.

https://doi.org/10.1182/blood.V122.21.2762.2762

Published: 2013

Journal Articles

Congenital dyserythropoietic anemias: molecular insights and diagnostic approach

Achille Iolascon, Hermann Heimpel, Anders Wahlin, Hannah Tamary

Blood (2013) 122 (13): 2162–2166.

https://doi.org/10.1182/blood-2013-05-468223

Published: 2013

Journal Articles

Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23

Maria Liljeholm, Andrew F. Irvine, Ann-Louise Vikberg, Anna Norberg, Stacy Month, Herbert Sandström, Anders Wahlin, Masanori Mishima, Irina Golovleva

Blood (2013) 121 (23): 4791–4799.

https://doi.org/10.1182/blood-2012-10-461392

Published: 2013

Includes: Multimedia, Supplemental data

Journal Articles

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Jatin J. Shah, M.D., Jeffrey A. Zonder, MD, Adam Cohen, MD, William Bensinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, M.D., Ph.D., R. Donald Harvey, PharmD, Muneer H. Abidi, MD, Sheeba K. Thomas, MD, Duncan Walker, PhD, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 449.

https://doi.org/10.1182/blood.V120.21.449.449

Published: 2012

Journal Articles

Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)

Brian Tunquist, Karin Brown, Gary Hingorani, Sagar Lonial, MD, Jonathan L. Kaufman, MD, Jeffrey A. Zonder, MD, Adam D Cohen, MD, William I. Bensinger, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D., Brandi Hilder, Ann Marie Ptaszynski, MD, Kevin Koch, Kevin Litwiler, Duncan Walker

Blood (2012) 120 (21): 1868.

https://doi.org/10.1182/blood.V120.21.1868.1868

Published: 2012

Journal Articles

Targeted Gene Disruption of Kinesin-3 Family Motors Unveils a Negative Regulatory Mechanism for Mouse Erythroblast Enucleation

Toshihiko Hanada, PhD, Yunzhe Lu, PhD, Athar H Chishti, Ph.D.

Blood (2012) 120 (21): 371.

https://doi.org/10.1182/blood.V120.21.371.371

Published: 2012

NARROW

Mitochondrial Regulation Is Essential for Erythroid Nuclear Clearance

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Kurowska M, Goudin N, Nehme NT, et al. Terminal transport of lytic granules to the immune synapse is mediated by the kinesin-1/Slp3/Rab27a complex. Blood . 2012;119(17): 3879-3889 .

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Whole Exome Sequencing Detecting Kinesin Family Gene Defects In Myeloid Neoplasm

Congenital dyserythropoietic anemias: molecular insights and diagnostic approach

Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM)

Targeted Gene Disruption of Kinesin-3 Family Motors Unveils a Negative Regulatory Mechanism for Mouse Erythroblast Enucleation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only